Andere Sprachen Hybio Pharmaceutical Co., Ltd.

Aktien

300199

CNE1000011T7

300199

Schlusskurs Shenzhen S.E. Andere Börsenplätze 00:00:00 17.05.2024			% 5 Tage	% 1. Jan.
12.2 ^CNY	+3.13%		-3.40%	-10.16%

26.04.	Hybio Pharmaceutical Co. Ltd. meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI
26.04.	Hybio Pharmaceutical Co. Ltd. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	26.04.
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	26.04.
Production Line of Hybio Pharma's Unit Passes Australian Regulator's Inspection	25.04.
Hybio Pharmaceutical Gets Regulatory Nod to Test Weight Management Injection; Shares Up 5%	18.04.
Hybio Pharmaceutical Gets Nod to Trial Semaglutide Injection; Shares Down 4%	06.12.
Hybio Pharmaceutical Receives $14.1 Million Worth of Orders from US Company; Shares Up 6%	06.11.
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	29.10.23
Hybio Pharmaceutical Gets Nod to Trial COVID-19 Nasal Spray	21.09.23
Hybio Lands $30 Million Bulk Pharma Chemical Supply Deal With Overseas Client	21.09.23
Hybio Pharmaceutical Co., Ltd.(XSEC:300199) added to S&P Global BMI Index	18.09.23
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	14.08.23
Hybio Pharmaceutical Co., Ltd. announced that it expects to receive CNY 254.12 million in funding	11.08.23
Hybio Pharmaceutical Registers Acetic Acid Pharmaceutical Ingredient	12.07.23
Hybio Pharma’s Carboprost Injection Granted New Indication for Vaginal Delivery	11.07.23
Hybio Pharmaceutical Gets Nod to Trial Linaclotide Capsules	17.05.23
Shenzhen Huaxiang Zhiyuan Biotechnology Center (Limited Partnership) and Hybio Biotechnology Co., Ltd. from Zhou Zhenke for CNY 0.15 million.	27.04.23
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	26.04.23
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	26.04.23
Li Xiulan completed the acquisition of 5% stake in Hybio Pharmaceutical Co., Ltd. (SZSE : 300199) from Zeng Shaogui, Zeng Shaoqiang and Zeng Shaobin.	28.03.23
Hybio Pharma’s COVID-19 Nasal Spray Wins FDA Nod For Clinical Trial	28.02.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Hybio Pharmaceutical Co., Ltd.

Aktien

300199

CNE1000011T7

300199

Andere Sprachen

Filter